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CD4+ lymphocyte count and human immunodeficiency virus (HIV) type 1 RNA level are
useful for determining when to initiate antiretroviral therapy but are not used widely in devel-
oping countries due to the high cost. Heat-denatured protein 24 (p24) antigen is an inexpensive
assay that predicts disease progression among persons with advanced disease but has not been
assessed among persons with early-stage disease. Plasma levels of heat-denatured p24 antigen
were quantified in baseline study-visit specimens obtained from injection drug users enrolled in
a longitudinal cohort study of HIV-1 infection. Of the 494 study participants (median initial
CD4+ lymphocyte count, 518 lymphocytes/mm3), 90 (18%) progressed to acquired immunode-
ficiency syndrome within 5 years. p24 antigen level correlated with both CD4+ lymphocyte count
( ; ) and HIV-1 RNA level ( ; ). p24 antigen level 15 pg/mLrp0.34 P ! .0001 rp 0.55 P ! .0001
predicted disease progression, comparable with that of cutoff CD4+ lymphocyte count !350
lymphocytes/mm3 and HIV-1 RNA level 130,000 copies/mL. Heat-denatured p24 antigen level
predicted subsequent clinical disease progression in early-stage HIV-1 infection and correlated
with both CD4+ lymphocyte count and HIV-1 RNA level.
It is estimated that 36 million people are infected with human
immunodeficiency virus (HIV) type 1, of whom 95% live in the
developing world [1]. CD4 lymphocyte count and HIV-1 RNA
level are excellent predictors of clinical disease progression and
response to therapy [2] and are used to determine when to initiate
therapy [3]. Although antiretroviral therapy is becoming more
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affordable in developing countries, CD4 lymphocyte and HIV-
1 RNA monitoring remain costly. A less expensive test with which
to monitor disease progression in this setting would allow for
appropriate use of antiretroviral therapy.
Signal amplification–boosted HIV-1 protein 24 (p24) antigen
level in heat-denatured plasma is comparable with HIV-1 RNA
level in predicting CD4 lymphocyte decline and survival among
persons with advanced HIV disease [4] and is effective in moni-
toring response to therapy [5].‘
However, the ability of heat-denatured p24 antigen level to
predict clinical disease progression among adults with early-
stage HIV-1 infection has not been assessed. Such a capability
is necessary to determine whether the test can be used to decide
when to initiate therapy. Although native p24 antigen can be
detected in patients with advanced HIV disease and levels cor-
relate with response to therapy [6], p24 antigen often is not
detected in patients during early-stage disease because of anti-
gen-antibody complexes [7]. The heat-denatured p24 antigen
assay dissociates these complexes, thereby increasing the ability
of the assay to detect p24 antigen in patients during early-stage
disease. If the predictive power of heat-denatured p24 antigen
level is comparable with that of CD4 lymphocyte count and/
or HIV-1 RNA level, the test, given the low cost [8], could be
of particular benefit in countries with the highest burden of
HIV-1 infection.
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Table 1. Clinical and demographic characteristics of the 494 study
participants.
Characteristic Value
Black race, % 97
Age, years 33.9 (29.8–38.2; 6.5)
CD4 lymphocyte count, lymphocytes/mm3 518 (356–719; 308)
Log10, CD4
1a 2.72 (2.55–2.86; 0.24)
bDNA, copies/mL 7586 (1438–27,080; 41,634)
Log10 bDNA
a 3.88 (3.16–4.43; 0.81)
p24, pg/mL 0.605 (0.13–4.72; 38.39)
Log10 p24
a 0.218 (0.88 to 0.67; 1.03)
NOTE. Data are median (interquartile range; SD), except where noted.
a Skewness, !0.5; kurtosis !1.0, consistent with no outliers.
Table 2. Cox proportional hazards univariate models of hazard ratio
(HR) and standardized HR (SHR) of progression to AIDS within 5
years of baseline visit.
Model Variable HR (95% CI) SHR (95% CI) Wald x2 P
A Log(CD4  1) 0.05 (0.022–0.127) 2.04 (1.64–2.50) 43.80 !.0001
B Log(bDNA) 2.65 (1.96–3.57) 2.18 (1.71–2.77) 40.36 !.0001
C Log(p24) 2.05 (1.66–2.53) 2.09 (1.69–2.60) 45.47 !.0001
NOTE. CI, confidence interval.
Subjects and Methods
Study population. Participants were injection drug users en-
rolled in a longitudinal cohort study who were HIV-1 seropositive
at their baseline visit; they were followed-up semiannually [9].
Blood samples were obtained for CD4 lymphocytes, and plasma
samples were frozen. Persons were excluded if their CD4 lym-
phocyte count and HIV-1 RNA level were not available at the
baseline visit. AIDS-defining diagnoses and deaths occurring dur-
ing the 5 years after each participant’s initial visit at which blood
samples were obtained were included in the analysis. Ascertainment
of clinical endpoints was performed, as described elsewhere [10].
Laboratory techniques. T cell subsets were measured according
to modified whole-blood staining methods and by use of flow cyto-
metric procedures. HIV-1 RNA level in plasma was quantified by
using a second-generation (version 2.0), branched-chain DNA sig-
nal amplification assay (Chiron), with a quantification limit of 500
copies/mL and a linear dynamic range of – cop-2 65.0 10 1.5 10
ies/mL. Heparinized plasma specimens for the quantitation of HIV-
1 RNA levels were processed within 4–6 h of collection and were
stored at 70C until testing (without thawing and refreezing).
Undetectable virus loads were coded as the lower limit of detection
(i.e., 500 copies/mL). HIV-1 p24 antigen levels were quantified as
described elsewhere [4].
Statistical analysis. Associations among CD4 lymphocyte
count, HIV-1 RNA level, and p24 antigen level were compared by
using Spearman’s rank correlation coefficients, with confidence in-
tervals (CIs) that were calculated by using Fisher’s Z-transformation.
Log transformation was used for CD4 lymphocyte count, HIV-1
RNA level, and p24 antigen level, because it improved skewness,
kurtosis, and other measures of normality. Cox proportional hazards
models determined univariate and multivariate baseline visit predic-
tors of subsequent progression to AIDS. Kaplan-Meier survival anal-
ysis of time to AIDS was performed; the significance of the difference
of the curves was assessed by use of the log-rank test. To facilitate
comparison of hazard ratios among CD4 lymphocyte count, HIV-
1 RNA level, and p24 antigen level, we determined standardized
hazard ratios, which represent the change in hazard for a 1 SD change
of the log-transformed variables. The hazard ratios for a 1 SD in-
crease in log-transformed HIV-1 RNA and p24 antigen level, as well
as a 1 SD decrease in log-transformed CD4 lymphocyte count, are
reported.
Results
Of the 665 HIV-1–infected cohort participants, 13 had miss-
ing baseline CD4 lymphocyte counts, and 157 did not have
sufficient plasma samples available to perform HIV-1 RNA and
p24 antigen analyses. One participant developed AIDS after
the initial study visit (before a blood sample was drawn) and
thus was excluded. Thus, 494 participants were included in the
study; the clinical and demographic characteristics of these par-
ticipants are listed in table 1. HIV-1 RNA was undetectable in
55 participants, and heat-denatured p24 antigen was not de-
tected in 1 patient. During the first 5 years after the baseline
visit, participants reported no antiretroviral therapy use at 85%
of study visits, dual nucleoside reverse-transcriptase inhibitor
therapy at 15% of visits, and highly active antiretroviral therapy
at 0.1% of visits. Of the 494 participants, 90 (18%) developed
AIDS within 5 years of the baseline visit; only 2 (4%) of 55
with undetectable HIV-1 RNA levels developed AIDS. There
were 94 deaths, of whom 48 had AIDS, during the 5-year fol-
low-up period.
Baseline CD4 lymphocyte count, HIV-1 RNA level, and heat-
denatured p24 antigen level were statistically significantly cor-
related with each other. Heat-denatured p24 antigen level cor-
related more strongly with HIV-1 RNA level ( ; 95% CI,rp 0.55
0.50–0.62; ) than with CD4 lymphocyte count (P ! .0001 rp
; 95% CI, 0.42 to 0.26; ). The weakest cor-0.34 P ! .0001
relation was between HIV-1 RNA level and CD4 lymphocyte
count ( ; 95% CI, 0.29 to 0.12; ).rp0.21 P ! .0001
Cox proportional hazards models were constructed to assess
predictors of progression to AIDS at the baseline visit (tables
2 and 3). For these analyses, 28 participants were excluded,
because they had no follow-up visits. In univariate models,
CD4 lymphocyte count, HIV-1 RNA level, and heat-dena-
tured p24 antigen level were all highly predictive of subsequent
disease progression. To best compare the relative ability of all
3 variables to predict disease progression, the standardized haz-
ard ratio of these variables, which reflects the change in hazard
for a 1 SD change in the variable, was used. In these stan-
dardized univariate models, a 1 SD decrease in log(CD4) or
increase in log(bDNA) or log(p24) each resulted in a hazard
ratio of disease progression of ∼2. All 3 measures were statis-
tically equivalent and had comparable x2 results.
In Cox multivariate models with 2 variables, the combination
of HIV-1 RNA level and CD4 lymphocyte count was the
strongest predictor of disease progression (full-model x2, 75.48);
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Table 3. Cox proportional hazards multivariate models of hazard ratio (HR) and standardized HR
(SHR) of progression to AIDS within 5 years of baseline visit.
Model, variable HR (95% CI) SHR (95% CI) Partial Wald x2,a P Full-model LHR x2,b
A
Log(p24) 1.72 (1.38–2.14) 1.75 (1.39, 2.19) 23.68 !.0001 65.55
Log(CD4  1) 0.12 (0.048–0.31) 1.67 (1.33–2.08) 19.93 !.0001
B
Log (p24) 1.65 (1.30–2.09) 1.67 (1.31–2.14) 17.21 !.0001 62.90
Log(bDNA) 2.00 (1.43–2.80) 1.74 (1.33–2.28) 16.30 !.0001
C
Log (CD4  1) 0.093 (0.040–0.22) 1.77 (1.43–2.17) 30.77 !.0001 75.48
Log(bDNA) 2.41 (1.76–3.30) 2.02 (1.57–2.60) 30.20 !.0001
D
Log(p24) 1.37 (1.07–1.75) 1.38 (1.07–1.78) 6.33 .01 81.90
Log (CD4  1) 0.134 (0.055–0.33) 1.61 (1.30–2.00) 19.45 !.0001
Log(bDNA) 2.01 (1.42–2.85) 1.75 (1.32–2.31) 15.55 !.0001
NOTE. CI, confidence interval; LHR, likelihood ratio. HR is per 1 log increase in CD4, bDNA, and p24; SHR
is per 1 SD decrease in log( ) and per 1 SD increase in log(bDNA) and log(p24). When log10 was used forCD4 1
p24, a value of 0 was treated as 0.001 (i.e., log10 [0.001]). All CD4 lymphocyte, bDNA, and p24 levels were from
the initial study visit.
a Based on maximum LHR.
b Based on differences in 2 log LHR for the full model and a model without covariates. Full-model x2 exceeds
the sum of partial x2, because the partial x2 exclude predictive associations shared by multiple components.
however, the combination of heat-denatured p24 antigen level
and CD4 lymphocyte count also was a strong predictor of
subsequent disease progression (table 3). The standardized haz-
ard ratios of disease progression were similar for each variable
included in the models.
The ability of the 3 variables to predict clinical disease pro-
gression, according to a specific cutoff, was assessed. Cutoffs
for CD4 lymphocyte count and HIV-1 RNA level in HIV
treatment guidelines (CD4 lymphocyte count, !350 CD4
lymphocytes/mm3, and HIV-1 RNA level 130,000 copies/mL,
respectively, for the version 2.0 b-DNA assay) were assessed
[3], because these cutoffs represented approximately the first
and third quartile, respectively, of the distribution of these vari-
ables among our study population. The third quartile of heat-
denatured p24 antigen level also was assessed (15 pg/mL). In
this cohort, 77% had a CD4 lymphocyte count 1350 lympho-
cytes/mm3, 77% had HIV-1 RNA level30,000 copies/mL, and
76% had p24 antigen level 5 pg/mL. Each of these 3 cutoffs
equally predicted progression to AIDS during the 5 years of
follow-up, with very similar survival curves for the low-risk and
high-risk groups (figure 1).
Discussion
In this large study among persons with early HIV-1 disease
(median baseline CD4 lymphocyte count, 518 lymphocytes/
mL3), baseline heat-denatured p24 antigen level was a strong
predictor of subsequent progression to AIDS and was statis-
tically equivalent (as indicated by standardized hazard ratios
and model x2) to CD4 lymphocyte count and HIV-1 RNA
level. This was demonstrated in Cox univariate proportional
hazards models of disease progression, as well as in Cox multi-
variate models that adjusted for CD4 lymphocyte count and
HIV-1 RNA level. Heat-denatured p24 antigen level also cor-
related with CD4 lymphocyte count and HIV-1 RNA level,
both of which are strong predictors of disease progression [2].
The p24 antigen threshold (15 pg/mL) was prognostically
equivalent to that of CD4 lymphocyte count (!350 lympho-
cytes/mm3) and HIV-1 RNA level (130,000 copies/mL; b-DNA
assay version 2.0), which are cutoffs used in guidelines for the
initiation of antiretroviral therapy [3].
There were differences in the variability of the tests for CD4
lymphocyte count, HIV-1 RNA level, and heat-denatured p24
antigen level in this cohort, as demonstrated by differences in
the interquartile ranges of the log-transformed data (table 1).
The hazard ratios in the nonstandardized Cox proportional
hazards models were greatly influenced by these differences in
variability. However, in Cox univariate and multivariate pro-
portional hazards models, in which the relative hazard of the
3 log-transformed variables was standardized to the SD, CD4
lymphocyte count, HIV-1 RNA level, and heat-denatured p24
antigen level were all very comparable in predicting clinical
disease progression; a 1 SD change in each variable resulted in
a 2-fold change in hazard (tables 2 and 3).
If only 1 test were available, this study would suggest that
heat-denatured p24 antigen level would be comparable with
that of HIV-1 RNA level or CD4 lymphocyte count in pre-
dicting disease progression. In addition, p24 antigen level pre-
dicted disease progression independent of HIV-1 RNA level
and CD4 lymphocyte count. Thus, p24 antigen level could be
used either alone or in combination with one or both of the
other tests. If used in combination, use with CD4 lymphocyte
count appears to be most beneficial.
Currently, the total cost (including indirect costs, equipment,
personnel, etc.) of conducting 1 CD4 lymphocyte count is $88,
and the cost of measuring 1 HIV-1 RNA level is $152 (Johns
Figure 1. Kaplan-Meier curves of progression to AIDS during 5 years of follow-up, according to baseline threshold levels of CD4 lymphocyte count, human immunodeficiency virus (HIV) type
1 RNA level, and heat-denatured protein 24 (p24) antigen level. Progression to AIDS according to the following cutoffs: 350 CD4 lymphocytes/mm3 (log-rank x2, 39.7; ), 30,000 HIV-1P ! .0001
RNA (b-DNA) copies/mL (log-rank x2: 35.8; ), and 5 pg/mL of p24 antigen (log-rank x2, 39.8; ).P ! .0001 P ! .0001
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Hopkins Hospital list prices). In contrast, the total cost for the
p24 antigen test is ∼$20 when used qualitatively [8] and $30
when used quantitatively. Because of the frequency with which
monitoring must be performed to assess clinical disease pro-
gression and response to therapy [3], the heat-denatured p24
antigen test would be much more affordable than currently
available tests. In addition, because of the stability of p24 anti-
gen, sample transport and storage is less demanding than that
required for HIV-1 RNA; the test is also easy to perform and
can be readily automated.
There are at least 3 limitations of this study. First, although
CD4 lymphocyte testing was conducted shortly after the par-
ticipant’s study visit, testing of HIV-1 RNA and p24 antigen
levels was performed on plasma specimens that had been frozen
and stored for several years. Previous studies have noted de-
creased levels of HIV-1 RNA [11] and p24 antigen [12] in stored
samples. If deterioration occurred in the specimens used in this
study and was not equivalent for both HIV-1 RNA and p24
antigen, this could affect the ability of each to predict disease
progression, as well as the comparison of this ability between
HIV-1 RNA and p24 antigen levels. Of note, a significant de-
crease in heat-denatured p24 antigen level over time has not been
observed (J.S., unpublished data). Second, the participants in
this cohort were predominantly US black persons, which could
limit generalization. There are conflicting data on whether HIV-
1 RNA levels differ by race; it is unknown whether p24 antigen
levels differ by race. Third, most of the study participants prob-
ably were infected with HIV-1 subtype B. Although a previous
study demonstrated that heat-denatured p24 antigen was more
sensitive than bDNA among persons with non-B subtypes [13],
the predictive value of heat-denatured p24 antigen among per-
sons with non-B subtype HIV-1 infection needs to be assessed.
Other p24 antigen assays have been limited by decreased
sensitivity in African versus North American patient popula-
tions, probably because of immune complexing of p24 antigen
in African patients [14]. Of note, however, the heat-denatured
p24 antigen assay is 99% sensitive and 100% specific among
HIV-infected infants in Africa [15]. Nonetheless, additional
studies of this assay in African adults are needed.
This study is important for several reasons. First, it establishes
heat-denatured p24 antigen as an excellent predictor of clinical
disease progression among persons with early-stage HIV-1 in-
fection, which correlates closely with CD4 lymphocyte count
and HIV-1 RNA level. Thus, it will be very useful for decisions
regarding the initiation of antiretroviral therapy. Second, al-
though heat-denatured p24 antigen level can be used in combi-
nation with HIV-1 RNA level and/or CD4 lymphocyte count
for predicting clinical disease progression, it also could be used
alone. This, together with its low cost, make it a very attractive
test, particularly in resource-poor settings.
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